Russ Lebovitz

CEO & CoFounder
Russ Lebovitz

About Russ Lebovitz

Dr. Russ Lebovitz brings in-depth expertise in managing biotech companies in the diagnostics field. His broad experience spans from R&D to early-stage to commercial product launch. 

Dr. Lebovitz has spearheaded global projects for Fortune 100 companies and venture-backed startups. The visionary CEO has forged strategic relationships with pharmaceutical companies and renowned clinicians worldwide.

Before his management career, Russ worked as a senior scientist and research physician for over 15 years.

Over his illustrative career, Dr. Lebovitz served on the faculty of Baylor College of Medicine at the Texas Medical Center in Houston and The Fox Chase Cancer Center in Philadelphia.

A champion for brain health drug development, Russ also works closely with the Alzheimer’s Drug Discovery Foundation (ADDF), playing the role of the principal investigator.

Always eager to collaborate on science, Dr. Russ Lebovitz plays an active part in research projects with the Center for Neurologic Study (CNS), the Michael J. Fox Foundation (MJFF), ALS Association (Golden West Chapter), and several other Lewy Body Dementia organizations.  

To date, Dr. Russ has appeared on 20+ brain health podcasts, spreading the message of early detection. 

Dr. Lebovitz received his M.D. and Ph.D. degrees from the Washington University School of Medicine.

"Improving the world.... One molecule at a time." - Russ Lebovitz

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.


Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.